Methods and compositions to treat cancer

Abstract

Embodiments provided herein relate to methods and compositions for treating cancer. Some embodiments include treating lung cancers and renal cancers.

1 . A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutical carrier, wherein formula (I) is: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1  is hydrogen, —OCH 3 , —CH 3 , —CF 3  or halogen; 
         R 2  is hydrogen or chlorine; 
         R 3  is hydrogen, chlorine or —CF 3 ; and 
         R 4  is 
       
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein:
 R 1  is hydrogen or halogen;   R 2  is hydrogen or chlorine;   R 3  is hydrogen or chlorine, when R 1  is hydrogen then R 2  and R 3  are chlorine, and when R 2  and R 3  are chlorine then R 1  is hydrogen.   
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein R 1  is selected from hydrogen, —OCH 3  and halogen; and R 2  and R 3  are hydrogen. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein R 1  is fluorine. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein formula (I) is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein formula (I) is: 
       
         
           
           
               
               
           
         
       
     
     
         7 . A method of treating a subject having a disorder selected from the group consisting of a lung cancer, a renal cancer, and an inflammatory disorder, comprising: administering an effective amount of a compound to a subject in need thereof, wherein the compound comprises formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1  is hydrogen, —OCH 3 , —CH 3 , —CF 3  or halogen; 
         R 2  is hydrogen or chlorine; 
         R 3  is hydrogen, chlorine or —CF 3 ; and 
         R 4  is 
       
       
         
           
           
               
               
           
         
       
     
     
         8 . The method of  claim 7 , wherein:
 R 1  is hydrogen or halogen;   R 2  is hydrogen or chlorine;   R 3  is hydrogen or chlorine, when R 1  is hydrogen then R 2  and R 3  are chlorine, and when R 2  and R 3  are chlorine then R 1  is hydrogen.   
     
     
         9 . The method of  claim 7 , wherein R 1  is selected from hydrogen, —OCH 3  and halogen; and R 2  and R 3  are hydrogen. 
     
     
         10 . The method of  claim 9 , wherein R 1  is fluorine. 
     
     
         11 . The method of  claim 7 , wherein formula (I) is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         12 . The method of  claim 7 , wherein formula (I) is: 
       
         
           
           
               
               
           
         
       
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 7 , wherein the disorder is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, rheumatoid arthritis, atherosclerosis, and restenosis. 
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 7 , wherein the subject is mammalian. 
     
     
         17 . (canceled) 
     
     
         18 . A method of inhibiting a neoplastic cell, comprising contacting the cell with an amount of a formula (I) sufficient to inhibit the cell, wherein formula (I) is: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1  is hydrogen, —OCH 3 , —CH 3 , —CF 3  or halogen; 
         R 2  is hydrogen or chlorine; 
         R 3  is hydrogen, chlorine or —CF 3 ; and 
         R 4  is 
       
       
         
           
           
               
               
           
         
       
     
     
         19 .- 38 . (canceled) 
     
     
         39 . The pharmaceutical composition of  claim 1 , wherein the compound of formula (I) has the structure of formula (II): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1  is hydrogen, —OCH 3 , or halogen; 
         R 2  is hydrogen or chlorine; 
         R 3  is hydrogen or chlorine. 
       
     
     
         40 . The method of  claim 7 , wherein the compound of formula (I) has the structure of formula (II): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1  is hydrogen, —OCH 3 , or halogen; 
         R 2  is hydrogen or chlorine; 
         R 3  is hydrogen or chlorine. 
       
     
     
         41 . The method of  claim 18 , wherein the compound of formula (I) has the structure of formula (II): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1  is hydrogen, —OCH 3 , or halogen; 
         R 2  is hydrogen or chlorine; 
         R 3  is hydrogen or chlorine. 
       
     
     
         42 .- 48 . (canceled)